細胞番号 : 細胞名 RCB0755 : OMC-3  update : 2022/08/18
細胞特性(Comment:英)			Mucinous cystadenocarcinoma. Said CA125,CA19-9 (+).
細胞特性(日)			卵巣癌（粘液性嚢胞腺癌）。CA125、CA19-9産生性といわれる。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)			A prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
使用条件(日)			営利目的か非営利目的かを問わず、いかなる使用につきましても、承諾者(寄託者)から承諾を得ることが必要です。
備考(英)
備考(日)
承諾者住所			× Japanese 住所 569-8686 大阪府 高槻市 大学町2-7 大阪医科薬科大学   医学部 病理学教室 山田 隆司 先生 Fax. 072-684-6513 English Address Osaka Medical and Pharmaceutical University 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan Dr.YAMADA Takashi Fax. +81-72-684-6513
提供申込書類(英)			Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日)			依頼書C-0001.pdf   承諾書C-0002.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf
			提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料			手数料とお支払いについてはこちらをご覧ください。
細胞基本情報		寄託者	Yamada, Takashi
		樹立者	Yamada, Takashi
		寄託日	1992
		動物種	_human < Mammals
		属名	Homo
		種名	sapiens
		人種	Japanese
		性別	Female
		齢	58 years
		採取組織	ovary
		病名	mucinous cystadenocarcinoma
		細胞分類	cancer
		初代培養日	1984
		細胞寿命	infinite
		細胞形態	epithelial-like
		Cellosaurus(Expasy)	CVCL_3354
細胞培養・検査情報			寄託時情報	ロット情報
	培地・試薬情報		培地・試薬一覧はこちらをご覧ください。
		培養形態		Adherent cells
		培地		HamF12 + 10% NBS
		抗生物質		Free
		継代方法		0.25% Trypsin
		継代密度		1 : 4 split
		継代・培地交換頻度		Subculture : once/2-3 weeks, Medium Renewal : 2 times/week
		培養最適温度		37 ℃
		二酸化炭素濃度		5 %
		凍結培地		Medium + 10% DMSO
		凍結方法		Slow freezing
		マイコプラズマ		(-)
		アイソザイム検査		LD, NP
		染色体検査		41-88(50) : /42(8),43(15),44(8),82(1),83(2)/
		個体識別検査		OK
画像情報			寄託時情報	ロット情報
文献情報		Reference(英)	10件
		Reference(日)	1件
		利用者成果(英)	13件
		利用者成果(日)	0件

ページトップへ

Reference(英)

888  Ueda M, Toji E, Noda S.  Germ line and somatic mutations of BRAF V599E in ovarian carcinoma  Int J Gynecol Cancer  2007  17(4):794-7  PubMed ID: 17309670   DOI: 10.1111/j.1525-1438.2006.00853.x

885  Ueda M, Hung YC, Chen JT, Chiou SH, Huang HH, Lin TY, Terai Y, Chow KC.  Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer  Gynecol Oncol  2006  102(2):173-81  PubMed ID: 16427687   DOI: 10.1016/j.ygyno.2005.12.009

886  Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M.  Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas  Clin Cancer Res  2005  11(9):3225-32  PubMed ID: 15867217   DOI: 10.1158/1078-0432.CCR-04-1148

887  Tumor angiogenesis and molecular target therapy in ovarian carcinomas  Tumor angiogenesis and molecular target therapy in ovarian carcinomas  Hum Cell  2005  18(1):1-16  PubMed ID: 16130895   DOI: 10.1111/j.1749-0774.2005.tb00052.x

80  Ueda M, Ueki M, Terai Y, Ueki K, Kumagai K, Fujii H, Yoshizawa K, Nakajima M.  Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells  Gynecol Obstet Invest  1999  48(3):221-8  PubMed ID: 10545752   DOI: 10.1159/000010160

79  Ueda M, Fujii H, Yoshizawa K, Kumagai K, Ueki K, Terai Y, Yanagihara T, Ueki M.  Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells  Jpn J Cancer Res  1998  89(12):1334-42  PubMed ID: 10081495   DOI: 10.1111/j.1349-7006.1998.tb00531.x

81  Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells  Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells  Invasion Metastasis  1998  18(4):176-83  PubMed ID: 10640903   DOI: 10.1159/000024510

82  Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M.  Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro  Jpn J Cancer Res  1996  87(5):524-33  PubMed ID: 8641991   DOI: 10.1111/j.1349-7006.1996.tb00255.x

1794  Yamada T, Ueda M, Otsuki Y, Ueki M, Sugimoto O  Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary.  Gynecol Oncol  1991  40:118-28  PubMed ID: 2010102   DOI: 10.1016/0090-8258(91)90102-b

78  Ueda M, Seiki Y, Yamada T, Okamoto Y, Tsurunaga T, Iwai E, Ueki M, Sugimoto O.  In vitro studies on the expression of c-myc oncogene product in gynecological cultured cancer cells  Nihon Sanka Fujinka Gakkai Zasshi  1991  43(11):1489-95  PubMed ID: 1940543

ページトップへ

Reference(日)

1738  岩井恵美、 植田政嗣、 鶴長建充、 清木康雄、 岡本吉明、 山田隆司、 植木実、 杉本修  Granulocyte Colony Stimulating Factor (G-CSF) および Erythropoietin (EPO) の腫瘍細胞増殖に与える影響  婦人科の世界  1991  43:893-899

ページトップへ

利用者成果(英)

11872  Koh I, Nosaka S, Sekine M, Sugimoto J, Hirata E, Kudo Y.  Regulation of REG4 Expression and Prediction of 5-Fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma.  Cancer Genomics Proteomics  2019    PubMed ID: 31659102   DOI: 10.21873/cgp.20151

9647  Koh I, Hinoi T, Sentani K, Hirata E, Nosaka S, Niitsu H, Miguchi M, Adachi T, Yasui W, Ohdan H, Kudo Y.  Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.  Cancer Med  2016  5:1546-55  PubMed ID: 27060927   DOI: 10.1002/cam4.697

13459  Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.  Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging  Oncotarget  2016  7(20):29577-91.  PubMed ID: 27102436   DOI: 10.18632/oncotarget.8807

7132  Zhao S, Ma Y, Huang X.  Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling.  Int J Clin Exp Pathol  2015  8:10412-9  PubMed ID: 26617749

14956  Takata A, Terauchi M, Hiramitsu S, Uno M, Wakana K, Kubota T.  Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells  Int J Gynecol Cancer  2015  25(3):372-9  PubMed ID: 25514350   DOI: 10.1097/IGC.0000000000000340

13692  Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S.  NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression  PLoS One  2014  9(2):e88347.  PubMed ID: 24533079   DOI: 10.1371/journal.pone.0088347

15560  Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.  Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.  Cancer Sci  2008  99:2365-72  PubMed ID: 19032364   DOI: 10.1111/j.1349-7006.2008.00988.x

2934  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672   DOI: 10.1158/1078-0432.ccr-03-0510

6401  Tsuchiya Y, Nakajima M, Itoh S, Iwanari M, Yokoi T.  Expression of aryl hydrocarbon receptor repressor in normal human tissues and inducibility by polycyclic aromatic hydrocarbons in human tumor-derived cell lines.  Toxicol Sci  2003  72(2):253-9  PubMed ID: 12655030   DOI: 10.1093/toxsci/kfg022

6402  Nakajima M, Iwanari M, Yokoi T.  Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells.  Toxicol Lett  2003  144(2):247-56  PubMed ID: 12927368   DOI: 10.1016/s0378-4274(03)00216-9

6404  Tsuchiya Y, Nakajima M, Yokoi T.  Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene.  J Biochem  2003  133(5):583-92  PubMed ID: 12801909   DOI: 10.1093/jb/mvg075

6399  Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T.  Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.  Arch Toxicol  2002  76(5-6):287-98  PubMed ID: 12107646   DOI: 10.1007/s00204-002-0340-z

6162  Yamada A, Kawano K, Harashima N, Niiya F, Nagai K, Kobayashi T, Mine T, Ushijima K, Nishida T, Itoh K.  Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.  Cancer Immunol Immunother  1999  48(2-3):147-52  PubMed ID: 10414469   DOI: 10.1007/s002620050559

ページトップへ

利用者成果(日)